The multi-kinase inhibitor Sorafenib is currently the only FDA-approved drug available for the treatment of advanced HCC [31], and here we demonstrate that the poor clinical efficacy of Sorafenib can be significantly enhanced by simultaneous administration of the TLR3 agonist poly-ICLC. Here, TLR3 is linked to hepatocellular carcinoma.